FDA Grants Fast Track Status to Cystic Fibrosis Therapy QR-010 by ProQR
Cystic Fibrosis, News
ProQR Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its molecule QR-010 for the treatment of cystic fibrosis (CF) patients who have the deltaF508 mutation in ... Read more